Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: Evaluation of the new union internationale contre le cancer/American joint cancer committee staging system

Annals of Surgery

Volumn 253, Issue 4, 2011, Pages 689-698

  Gertler, Ralf ^a   Stein, Hubert J ^b   Langer, Rupert ^c   Nettelmann, Marc ^b   Schuster, Tibor ^a   Hoefler, Heinz ^c   Siewert, Joerg Ruediger ^d   Feith, Marcus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

^c Institut für Pathologie und Pathologische Anatomie   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953183993     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31821111b5     Document Type: Article

References (28)

1. Union Internationale Contre le Cancer. Oesophagus including Oesophagogastric Junction. In: Sobin LH, Gospodarowicz M, Wittekind C, eds. TNM Classification of Malignant Tumours. 7th ed. New York, NY: Wiley-Blackwell; 2009:66-72.
2. Union Internationale Contre le Cancer. TNM Classification of Malignant Tumours. 6th ed. New York, NY: Wiley-Liss; 2002.
3. Wood M. Statistical interference using bootstrap confidence intervals. Signifi- cance. 2004;1(4):180-182.
4. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337-344. (Pubitemid 30422619)
5. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172. (Pubitemid 351193639)
6. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
7. Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190:562-572.
8. Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520-530.
9. Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376-384.
10. Siewert JR, Stein HJ, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234:360-367.
11. Barbour AP, Jones M, Gonen M, et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol. 2008;15:2894-2902.
12. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classifi- cation. Ann Surg. 2005;242:684-692. (Pubitemid 41567124)
13. Rizk N, Venkatraman E, Park B, et al. American Joint Committee on Cancer staging system. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006;132:1374-1381.
14. HofstetterW,CorreaAM, BekeleN, et al. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg. 2007;84:365-373.
15. Rice TW, Blackstone EH, Rybicki LA, et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg. 2003;125:1103-1113. (Pubitemid 36644888)
16. Feith M, Stein HJ, Siewert JR. Pattern of lymphatic spread of Barrett's cancer. World J Surg. 2003;27:1052-1057. (Pubitemid 37186242)
17. Ichikura T, Tomimatsu S, Okusa Y, et al. Comparison of the prognostic significance between the number of metastatic lymph nodes and nodal stage based on their location in patients with gastric cancer. J Clin Oncol. 1993;11:1894-1900. (Pubitemid 23304613)
18. Roder JD, B̈ottcher K, Busch R, et al. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer. 1998;82:621-631. (Pubitemid 28090271)
19. Hermanek P, Altendorf-Hofmann A, Mansmann U, et al. Improvements in staging of gastric carcinoma from using the new edition of TNMclassification. Eur J Surg Oncol. 1998;24:536-541. (Pubitemid 28566900)
20. Aurello P, D'Angelo F, Rossi S, et al. Classification of lymph node metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature. Am Surg. 2007;73:359-566.
21. Stein HJ, Feith M, Bruecher BL, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg. 2005;242:566-573.
22. Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004;240:962-972.
23. Altorki N, KentM, Ferrara C, et al. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236:177-183. (Pubitemid 34809536)
24. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347: 1662-1669. (Pubitemid 35340784)
25. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992-1000. (Pubitemid 350179188)
26. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am. 2006;15:751-764. (Pubitemid 44499032)
27. American Joint Committee on Cancer. AJCC Cancer Staging Handbook. 6th ed. Philadelphia, PA: Lippincott-Raven; 2002: 3-8, 91-103.
28. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.